Latest Conference Articles

Susan F. Slovin, MD, PhD, from Memorial Sloan-Kettering Cancer Center, summarizes the development process of an effective immunotherapy for the treatment men with prostate cancer.

Hormonal therapies that target androgen are the focus of several ongoing clinical trials for the treatment of advanced prostate cancer, and as more data accrues, clinicians are gaining valuable insight as to how these drugs can best be used to manage the disease.

Following the recent flurry of FDA approvals for prostate cancer medications, oncologists are grappling with questions about which combinations or sequences of those therapies might improve outcomes for patients.

Leonard G. Gomella, MD, from the Thomas Jefferson University Hospital, describes the identification of appropriate surrogate endpoints for the evaluation of new therapies for patients with metastatic castration-resistant prostate cancer.

This year marks the 30th Annual Miami Breast Cancer Conference, a milestone for Daniel A. Osman, MD, and his wife Lois, who together launched the gathering in 1983 with fewer than 100 attendees and a focus on the then relatively new domain of lumpectomies in breast cancer treatment.

Donna Shalala, PhD, President, University of Miami, discusses the new healthcare reform in the U.S.

Physicians wondering how the Affordable Care Act (ACA) will impact their practices heard a robust defense of the new law from Donna E. Shalala, PhD, on Saturday.

Martine Piccart, MD, PhD, discusses the implications of the HERA trial, which looked at two years compared with one year of trastuzumab after adjuvant chemotherapy in women with HER2-positive breast cancer.

As the genomic era in oncology unfolds, the development of new therapeutics increasingly will involve targeting a range of mutations simultaneously, requiring a "next-generation clinical trials system" to match the advances that technology is delivering.

Two large clinical trials are expected to define the impact that employing genomic tests in treatment decisions has on survival outcomes, according to Martine J. Piccart, MD, PhD.

Oncology leaders are bracing for a host of changes in the healthcare system, not only as a result of the recently upheld insurance reform legislation but also because of continued pressure to control the ever-rising cost of cancer care.

Lisa A. Carey, MD, Professor of Medicine, University of North Carolina at Chapel Hill, discusses the field of psycho-oncology.

Burnout is described as a syndrome of "emotional exhaustion, depersonalization, and feelings of low personal accomplishment," and is an increasingly problematic condition among physicians for a multitude of reasons.

The incidence of adverse effects with regorafenib in metastatic colorectal cancer is highest during the first treatment cycle and then diminishes over time.

Hope S. Rugo, MD, at the University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, discusses the standard for front-line chemotherapy in patients with breast cancer.

An interview with Debu Tripathy, MD, summarizing noteworthy results from the 2012 ASCO Annual Meeting and SABCS, including clinical studies in local, adjuvant, and metastatic breast cancer therapies.

Capecitabine produces similar local disease control with lower toxicity versus gemcitabine when combined with radiotherapy following induction chemotherapy in patients with locally advanced pancreatic cancer.

FOLFOXIRI plus bevacizumab improved progression-free survival and response rates with a modest increase in side effects compared with FOLFIRI plus bevacizumab in patients with unresectable metastatic colorectal cancer.

Complete neoadjuvant treatment may represent a well-tolerated alternative to the current standard treatment sequence of adjuvant chemotherapy following chemoradiation and surgery.

William C. Huang, MD, from the New York University Langone Medical Center, discusses findings from a SEER database analysis that compared surveillance to surgical resection in elderly patients with small renal masses.

The 2013 Genitourinary Cancers Symposium was held at the Rosen Shingle Creek, Orlando, Florida, from February 14-16.

Matthew Cooperberg, MD, MPH, from the University of California, San Francisco, discusses the earlier administration of treatment with sipuleucel-T for men with prostate cancer.

Axitinib did not demonstrate superiority over sorafenib as first-line therapy for patients with metastatic renal cell carcinoma, on the endpoint of progression-free survival.

Tivozanib did not show a significant difference in overall survival when compared with sorafenib in patients with renal cell carcinoma who received up to one prior line of therapy excluding targeted agents.

Nicholas J. Vogelzang, MD, from the Comprehensive Cancer Centers of Nevada, discusses an updated analysis of the phase III ALSYMPCA trial that examined radium-223 dichloride in patients who have CRPC with bone metastases.

Combination targeted therapy did not significantly extend progression-free survival compared with single-agent bevacizumab in patients with advanced renal cell carcinoma.

Howard I. Scher, MD, from Memorial Sloan-Kettering Cancer Center, discusses the impact of corticosteroids on outcomes for men with metastatic castration-resistant prostate cancer receiving treatment with enzalutamide.

Robert J. Motzer, MD, from Memorial Sloan-Kettering Cancer Center, discusses the overall survival results from the phase III TIVO-1 study that compared tivozanib to sorafenib in patients with renal cell carcinoma.

The addition of dasatinib to standard therapy with docetaxel failed to improve survival and most other clinical endpoints in men with metastatic castration-resistant prostate cancer in the phase III READY trial.

An updated interim analysis of the COU-AA-302 trial upholds the benefits of abiraterone acetate in mildly symptomatic or asymptomatic patients with progressive mCRPC untreated with prior chemotherapy.